Comparative Pharmacology
Head-to-head clinical analysis: HALAVEN versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALAVEN versus TRABECTEDIN.
HALAVEN vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Deslanoside
"Trabectedin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrabectedin + Acetyldigitoxin
"Trabectedin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent